Skip to content
Baker Capital StrategiesMARKETS. FILINGS. PERSPECTIVE.
Powered by THEMA

BAKER CAPITAL STRATEGIES

Get the free weekly BCS email.

Selected company filings and market updates, delivered by email. Your first report will follow soon.

  • Your weekly BCS reportMarket updates and links to filings you can explore.
  • THEMA at launchWe’ll send directions for setting up your filing alerts when THEMA officially opens.

One signup for the weekly email and your free THEMA Basic account at launch.

Already registered or a CSW member?Log in to THEMA →

At least 8 characters. This also creates your free THEMA account for launch.

You’re signing up for the weekly BCS email and THEMA launch/setup updates. Unsubscribe using the link in any email. Privacy policy · Terms

BCS

Current Report · Items 5.02 · 8-K

Rocket Pharmaceuticals, Inc.

RCKTNASDAQEQUITYCurrent

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements

Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Severance and Change in Control Program On August 21, 2026, the Board of Directors (the “Board”) of Rocket Pharmaceuticals, Inc. (the “Company” or “Rocket”) adopted the Rocket Pharmaceuticals, Inc. Severance and Change in Control Program (the “Program”).…

Filed Aug 27, 2026Accepted Aug 27, 2026, 4:06 PM EDTCIK 1281895Accession 0001140361-26-034689
Share

Company context

Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) is a fully integrated commercial-stage biotechnology company developing genetic medicines for rare and life-threatening diseases, with a strategic focus on inherited cardiovascular disorders and additional programs in hematology and immunology. Rocket's cardiovascular portfolio includes three clinical-stage gene therapy programs targeting hypertrophic, arrhythmogenic, and dilated cardiomyopathies, together representing one of the broadest pipelines focused on inherited heart disease. The Company’s integrated platform combines proprietary adeno-associated virus (AAV) manufacturing capabilities and extensive clinical experience in cardiac gene therapy.

Current securities

Historical securities (1)

Recent company filings

  1. Entry into a Material Definitive Agreement · Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement · Unregistered Sales of Equity Securities · Regulation FD DisclosureOct 6, 2026
  2. Regulation FD DisclosureSep 15, 2026
  3. 144 filingSep 11, 2026
  4. 25-NSE - filed by Nasdaq Stock Market LLC regarding ROCKET PHARMACEUTICALS, INC.Sep 2, 2026
  5. 144 filingAug 18, 2026

Disclosure sections

Items 5.02

Select an item to read the extracted section. The as-filed document remains the primary evidence.

Item 5.02Item 5.02 - Departure/Election of Directors
Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Severance and Change in Control Program On August 21, 2026, the Board of Directors (the “Board”) of Rocket Pharmaceuticals, Inc. (the “Company” or “Rocket”) adopted the Rocket Pharmaceuticals, Inc. Severance and Change in Control Program (the “Program”). The Program provides severance benefits to eligible employees of the Company, including its executive officers, in connection with certain qualifying terminations of employment, including terminations occurring in connection with a change in control of the Company. All Rocket employees in the United States who are not covered by another agreement or arrangement with the Company that provides for severance benefits are eligible for severance under the Program, provided that to be eligible for severance benefits not associated with a Change in Control (as defined in the Program), employees must have been employed at Rocket for at least one year. Under the Program, upon a qualifying termination without “Cause” or resignation for “Good Reason” (each as defined in the Program) that does not occur in connection with a Change in Control, eligible employees are entitled to receive: For the CEO, fifteen months base salary and health care allowance continuation; ─────────────────────────────────────────────────────────────────────────────────── For the Section 16 Executive Leadership Team (“ELT”) members, twelve months base salary and health care allowance continuation; ─────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────── For the non-Section 16 ELT members and Senior Vice Presidents, nine months base salary and health care allowance continuation; ────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────── For Vice Presidents, six months base salary and health care allowance continuation; ─────────────────────────────────────────────────────────────────────────────────────── For Directors, three months base salary and health care allowance continuation in the event of a termination without Cause and no severance benefits in the event of a resignation for Good Reason; and ─────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────── For Senior Managers and below, two months base salary and health care allowance continuation in the event of a termination without Cause and no severance benefits in the event of a resignation for Good Reason. ──────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────── Under the Program, upon a qualifying termination without Cause or resignation for Good Reason occurring within twelve months following a Change in Control (or, for the Company’s Chief Executive Officer and Section 16 officers, within three months prior to and twelve months following a Change in control), eligible employees are entitled to receive: For the CEO, eighteen months base salary and health care allowance continuation, 100% of target bonus for the year of termination and a prorated target bonus for the year of termination; ────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────── For the Section 16 ELT members, twelve months base salary and health care allowance continuation, 100% of target bonus for the year of termination and a prorated target bonus for the year of termination; ────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────── For the non-Section 16 ELT members and Senior Vice Presidents, twelve months base salary and health care allowance continuation and 100% of target bonus for the year of termination; ───────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────── For Vice Presidents, nine months base salary and health care allowance continuation and 100% of target bonus for the year of termination; ───────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────── For Directors, six months base salary and health care allowance continuation; and ───────────────────────────────────────────────────────────────────────────────────── For Senior Managers and below, three months base salary and health care allowance continuation. ─────────────────────────────────────────────────────────────────────────────────────────────────── Severance benefits under the Program are contingent on the eligible employee’s execution and non-revocation of a release of claims in favor of the Company. The Program supersedes prior severance arrangements for eligible employees, except that the Board or senior management may approve individual arrangements providing for different levels of severance benefits, which would supersede the Program for the applicable individual. The foregoing description of the Program is only a summary and is qualified in its entirety by reference to the full text of the Program, a copy of which will be filed as an exhibit to the Company’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2026. Executive Employment Agreements On August 21, 2026, the Company entered into an Executive Employment Agreement (the “Shah Employment Agreement") with Gaurav Shah, M.D., the Company's Chief Executive Officer, and an Executive Employment Agreement (the “Wilson Employment Agreement”) with Martin Wilson, the Company's General Counsel and Chief Corporate Officer. Additionally, on August 21, 2026, the Company entered into Amendment No. 1 to the Executive Employment Agreement (the “Stevens Amendment”) with Christopher Stevens, the Company's Chief Operating Officer, which amends the Executive Employment Agreement between the Company and Mr. Stevens dated July 7, 2025 (as amended, the “Stevens Employment Agreement”). The below descriptions of the Shah Employment Agreement, the Wilson Employment Agreement and the Stevens Amendment are only summaries and are qualified in their entirety by reference to the full text of such agreements, copies of which will be filed as exhibits to the Company’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2026. Shah Employment Agreement Pursuant to the Shah Employment Agreement, Dr. Shah is entitled to an annual base salary of $674,856 and a target annual incentive bonus equal to 60% of his base salary. If Dr. Shah’s employment is terminated by the Company for Cause or by Dr. Shah without Good Reason (each as defined in the Shah Employment Agreement), he is entitled to receive any accrued but unpaid base salary and accrued but unused paid time off, reimbursement for unreimbursed business expenses properly incurred by Dr. Shah and any employee benefits Dr. Shah may be entitled to under the Company’s employee benefit plans as of the termination date (such amounts, collectively, the “Accrued Amounts”). If Dr. Shah’s employment is terminated by the Company without Cause or by Dr. Shah for Good Reason, he is entitled to receive the Accrued Amounts and, subject to his execution and non-revocation of a release of claims: (i) a lump sum payment equal to 15 months of his base salary; (ii) any incentive bonus to which he is otherwise entitled for the prior fiscal year; and (iii) a lump sum amount equal to 15 months of COBRA premiums. If such a termination occurs within 12 months following a Change in Control (as defined in the Shah Employment Agreement), Dr. Shah is instead entitled to receive: (i) a lump sum payment equal to 18 months of his base salary; (ii) a lump sum amount equal to his target incentive bonus for the year of termination; (iii) a lump sum amount equal to his target incentive bonus prorated through the termination date; and (iv) a lump sum amount equal to 18 months of COBRA premiums. Wilson Employment Agreement Pursuant to the Wilson Employment Agreement, Mr. Wilson is entitled to an annual base salary of $547,313 and a target annual incentive bonus equal to 45% of his base salary. If Mr. Wilson’s employment is terminated by the Company for Cause or by Mr. Wilson without Good Reason (each as defined in the Wilson Employment Agreement), he is entitled to receive any accrued but unpaid base salary and accrued by unused paid time off, reimbursement for unreimbursed business expenses properly incurred by Mr. Wilson and any employee benefits Mr. Wilson may be entitled to under the Company’s employee benefit plans as of the termination date (such amounts, collectively, the “Accrued Amounts”). If Mr. Wilson’s employment is terminated by the Company without Cause or by Mr. Wilson for Good Reason, he is entitled to receive the Accrued Amounts and, subject to his execution and non-revocation of a release of claims: (i) a lump sum payment equal to 12 months of his base salary; (ii) any incentive bonus to which he is otherwise entitled for the prior fiscal year; and (iii) a lump sum amount equal to 12 months of COBRA premiums. If such a termination occurs within three months prior to, or 12 months following, a Change in Control (as defined in the Wilson Employment Agreement), Mr. Wilson is instead entitled to receive: (i) a lump sum payment equal to 12 months of his base salary; (ii) a lump sum amount equal to his target incentive bonus for the year of termination; (iii) a lump sum amount equal to his target incentive bonus prorated through the termination date; and (iv) a lump sum amount equal to 12 months of COBRA premiums. Stevens Amendment Pursuant to the Stevens Amendment, if Mr. Stevens’ employment is terminated by the Company without Cause or by Mr. Stevens for Good Reason (each as defined in the Stevens Amendment), he is entitled to receive, subject to his execution and non-revocation of a release of claims: (i) a lump sum payment equal to 12 months of his base salary; (ii) any incentive bonus to which he is otherwise entitled for the prior fiscal year; and (iii) a lump sum amount equal to 12 months of COBRA premiums. If such a termination occurs within three months prior to, or 12 months following, a Change in Control (as defined in the Stevens Amendment), Mr. Stevens is instead entitled to receive: (i) a lump sum payment equal to his base salary for the fiscal year of termination; (ii) a lump sum amount equal to his target incentive bonus for the year of termination; (iii) a lump sum amount equal to his target incentive bonus prorated through the termination date; and (iv) a lump sum amount equal to 12 months of COBRA premiums. Other than as set forth in the Stevens Amendment, the Stevens Employment Agreement remains unmodified and in full force and effect.

Privacy choices

BCS measures page use with Google Analytics using regional consent settings. You can change your preference here. Charts and market data remain available.

Essential functions — always available. Security, navigation, registration and remembering these choices.

Audience analytics

Analytics cookies are off by default for visitors Google identifies in the EEA, UK or Switzerland until allowed. Limited measurement without analytics cookies may still occur under those regional defaults.

TradingView charts, quotes and the economic calendar load automatically as page content. TradingView receives network and browser information and may collect its own usage analytics. This choice controls BCS’s Google Analytics only.

Google advertising is not enabled. Direct sponsor links do not load advertising trackers on BCS.

Turning analytics off stops future Google Analytics activity here. It does not erase information already received by the provider. Read the privacy policy.